It is worth noting the NCA comparison was limited to a small homogeneous population (Arm G v.s. cohort 1a and Arm C of study GO29365 for patients with R/R DLBCL taking pola 1.8 mg/kg in combination with BR). The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.